Plain-English translation of NCT07640997 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study testing how well aflibercept 8 mg works in real-world patients with neovascular age-related macular degeneration (nAMD)—a progressive eye condition that can cause vision loss. Researchers will follow two groups: people receiving this medication for the first time, and people who have received other treatments before. The goal is to understand whether and how well this treatment maintains or improves vision, and whether it's safe to use.
While this medication has been tested in clinical trials, doctors need to know how it actually performs in everyday practice with real patients—including those with different backgrounds and other health conditions. This study will help eye doctors decide when and how to use this treatment most effectively.
You likely qualify if…
You likely don't qualify if…
You will receive aflibercept 8 mg injections as part of your regular eye care treatment. Over 12 months, you'll have follow-up visits at 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months where doctors will measure your vision and take images of your eye to see how you're responding. You'll also report any side effects or changes you experience, helping researchers understand both how well the treatment works and how safe it is.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China